Gracell Bio
formerly Gracell BiotechnologiesAcquired- Business Model
- B2B
- Website
- gracellbio.com
- Total Funding
- $150.0M
- Last Round
- $150.0M Private EquityAug 2023
- Rounds
- 1
- Acquisition Date
- Dec 2023
About
Clinical-stage biopharmaceutical company developing innovative CAR-T cell therapies for cancer and autoimmune disease.
Summary
Gracell Bio is a Biotech company. It has raised $150.0M in total across 1 round, most recently a $150.0M Private Equity round in Aug 2023. Investors include AstraZeneca, Vivo Capital and Pivotal Life Sciences.
Funding History
Dec 2023
Sign up to see all 2 rounds
Private Equity through Acquisition — per-round amounts, valuations, and who invested in each round.
Investors
Similar Companies
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
China's leading mRNA biotech company developing therapeutics for cancer and infectious diseases.
Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...
Clinical-stage biotech developing next-generation CAR T-cell therapies for cancer patients aiming...
Clinical-stage biotechnology company developing T-cell engager therapeutics for autoimmune and in...
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/gracell-bio"><img src="https://indexed.vc/api/badge/company/gracell-bio" alt="Gracell Bio on Indexed.vc" width="260" height="76" /></a>